Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). (Q38865053)
Jump to navigation
Jump to search
scientific article published on 31 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). |
scientific article published on 31 March 2017 |
Statements
1 reference
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). (English)
1 reference
Sven Almer
1 reference
Jonas F Ludvigsson
1 reference
Jan Marsal
1 reference
Daniel Bergemalm
1 reference
Lina Vigren
1 reference
Jan Björk
1 reference
Michael Eberhardson
1 reference
Pontus Karling
1 reference
Charlotte Söderman
1 reference
SWIBREG Vedolizumab Study Group
1 reference
Pär Myrelid
1 reference
Mari Thörn
1 reference
Per Karlén
1 reference
Erik Hertervig
1 reference
Hans Strid
1 reference
Jonas Halfvarson
1 reference
31 March 2017
1 reference
1 reference
52
1 reference
6-7
1 reference
722-729
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference